Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a report released on Wednesday,Benzinga reports. Chardan Capital currently has a $18.00 target price on the stock.

Several other analysts have also commented on TNYA. Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research note on Monday, November 25th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $17.33.

Tenaya Therapeutics Stock Down 12.8 %

Shares of TNYA opened at $1.23 on Wednesday. Tenaya Therapeutics has a 52-week low of $0.99 and a 52-week high of $7.01. The stock has a fifty day simple moving average of $2.44 and a two-hundred day simple moving average of $2.72. The company has a market capitalization of $97.44 million, a PE ratio of -0.85 and a beta of 2.72.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. As a group, equities analysts anticipate that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TNYA. Synovus Financial Corp acquired a new stake in shares of Tenaya Therapeutics during the third quarter worth about $28,000. SG Americas Securities LLC acquired a new stake in Tenaya Therapeutics during the 3rd quarter worth approximately $49,000. The Manufacturers Life Insurance Company boosted its position in Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after buying an additional 7,000 shares during the period. Algert Global LLC acquired a new position in shares of Tenaya Therapeutics in the second quarter worth $74,000. Finally, XTX Topco Ltd increased its position in shares of Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after acquiring an additional 16,687 shares during the period. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.